Press Release

Jan, 05 2024

Vital Fluid: Unveiling the Significance and Life-Saving Potential of Blood Plasma in Medical Advancements

The Singapore blood plasma market is a crucial sector within the healthcare industry, playing a pivotal role in providing essential components for medical therapies. Blood plasma, the liquid component of blood, is rich in proteins and antibodies, making it a valuable resource for producing life-saving medications. Primarily utilized for life-saving therapies, blood plasma is a source of critical proteins and antibodies. As a small but highly developed healthcare ecosystem, Singapore prioritizes the safety and quality of blood plasma products, adhering to stringent regulatory standards.

Access Full Report at

Data Bridge Market Research analyzes that the Singapore Blood Plasma Market, which was USD 1,108.80 million in 2022, is expected to reach USD 2,209.35 million by 2030 and is expected to undergo a CAGR of 9.00% during the forecast period 2023 to 2030. The surge in chronic diseases such as cancer, autoimmune disorders, and hemophilia fuels demand for blood plasma therapies. Vital plasma-derived products such as immunoglobulin, clotting factors, and albumin play a pivotal role in treating these conditions, emphasizing the critical need for their accessibility and utilization in medical care.

Key Findings of the Study

Singapore Blood Plasma Market

Rising blood plasma export opportunities are expected to drive the market's growth rate

Positioned as a dependable supplier of premium blood plasma products, Singapore experiences a surge in export opportunities. The country's commitment to producing high-quality plasma-derived goods meets global standards and fuels economic growth within the sector. As international demand grows, the export of these essential medical resources becomes a significant driver, positively impacting Singapore's economy and further solidifying its role in the global blood plasma market.

Report Scope and Market Segmentation

Report Metric


Forecast Period

2023 to 2030

Base Year


Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Hyperimmune Globulin, Albumin, Factor VIII, Factor IX, Immunoglobulin, and Others), Mode of Delivery (Infusion Solutions, Gels, Sprays, Biomedical Sealants), Therapeutic Indication (Immunology, Oncology, Pulmonology, Rheumatology, Transplantation, Neurology, Hematology, Other), Application (Hypogammaglobulinemia, Immunodeficiency Diseases, Hemophilia, Von Willebrand's Disease (vWD), Others), End-User (Clinics, Hospitals, Other)

Market Players Covered

CSL Limited (Australia), Grifols, S.A. (Spain), Takeda Pharmaceutical Company Limited (Japan), and Octapharma AG (Switzerland) among others

Data Points Covered in the Report

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

The Singapore blood plasma market is segmented on the basis of type, mode of delivery, therapeutic indication, application, and end-user. 

  • On the basis of type, the Singapore blood plasma market is segmented into hyperimmune globulin, albumin, factor VIII, factor IX, immunoglobulin, and others
  • On the basis of mode of delivery, the Singapore blood plasma market is segmented into infusion solutions, gels, sprays, and biomedical sealants
  • On the basis of therapeutic indication, the Singapore blood plasma market is segmented into immunology, oncology, pulmonology, rheumatology, transplantation, neurology, hematology, and other
  • On the basis of application, the Singapore blood plasma market is segmented into hypogammaglobulinemia, immunodeficiency diseases, hemophilia, von willebrand's disease (VWD), and others
  • On the basis of end-user, the Singapore blood plasma market is segmented into clinics, hospitals, and other

Major Players

Data Bridge Market Research recognizes the following companies as the major Singapore blood plasma market players in Singapore blood plasma market are CSL Limited (Australia), Grifols, S.A. (Spain), Takeda Pharmaceutical Company Limited (Japan), and Octapharma AG (Switzerland)

Singapore Blood Plasma Market

Market Developments

  • In May 2023, Teva Pharmaceutical Industries Ltd. announced a strategic framework for future growth. With pillars centered on fortifying its commercial portfolio featuring AUSTEDO, AJOVY, UZEDYTM, and biosimilars, enhancing innovation in its pipeline, sustaining generics leadership, and strategic focus, the company aims to navigate a new era, ensuring resilience, competitiveness, and sustained success in the pharmaceutical landscape
  • In October 2022, Grifols marked a milestone with the inauguration of a state-of-the-art albumin purification and filling plant in Dublin, Ireland. This facility, situated at their global manufacturing and supply hub, represents a strategic move to enhance production capabilities for albumin, a critical plasma-derived product. The expansion strengthens Grifols' commitment to meeting global demand for high-quality medical solutions and underscores Dublin's pivotal role in the company's worldwide operations
  • In September 2022, CSL Behring K.K. achieved approval from Japan's Ministry of Health, Labour and Welfare for Berinert S.C. Injection 2000. This lyophilized human C1-esterase inhibitor concentrate is designed for subcutaneous injection in plasma derivative. Specifically developed for preventing acute hereditary angioedema (HAE) attacks, this approval marks a significant advancement in therapeutic options for individuals affected by this genetic disorder in Japan
  • In February 2020, EmCyte successfully acquired Cellmedix Holdings LLC, encompassing all assets of the U.S.-based company. This acquisition included ownership of Cellmedix's proprietary product system, the Centrepid Platelet Concentrator. EmCyte's strategic move enhances its product portfolio and technological capabilities, positioning the company to advance in the field of platelet concentration and reinforcing its commitment to innovation in the biomedical industry

For more detailed information about the Singapore blood plasma market report, click here –

Client Testimonials